Table 2.
Recombinant Immunotoxins that were mutated to decrease immunogenicity.
| Drug name | Target | Toxin description | Activity | References | ||
|---|---|---|---|---|---|---|
| IC50 (pM) | Relative activity (compared to PE38) (%) | Cell type | ||||
| Moxetumomab | CD22 | PE38 | 3.4 | 100 | CA46 | (65) |
| LO10 | PE24 with 5 point mutations to reduce B cell binding | 0.9 | 378 | (64) | ||
| LMB-T18 | PE24 with 6 point mutations to reduce T cell binding | 2.2 | 155 | (65) | ||
| LMB-T19 | PE24 with 10 point mutations to reduce B and T cell binding | 3.4 | 100 | Unpublished | ||
| SS1P | Mesothelin | PE38 | 47.5 | 100 | KLM1 | (66) |
| LMB-100/RG7787 | Humanized Fab and PE24 with 5 point mutations to reduce B cell binding | 9.9 | 480 | |||
| LMB-T20 | PE24 with 6 point mutations to reduce T cell binding | 13.1 | 363 | |||
| LMB-T14 | PE24 with 10 point mutations to reduce B and T cell binding | 27.9 | 170 | |||
| LMB-2 | CD25 | PE38 | 0.07 | 100 | HUT102 | (67) |
| LMB-2 T20 | PE38 with 6 point mutations to reduce T cell binding | 0.23 | 30 | |||
| LMB-142 | PE38 with 9 point mutations to reduce T cell binding | 0.69 | 10 | |||
| Tac-M18-PE24(T) | PE24 with C-C stabilizing linker and 6 point mutations to reduce T cell binding | 0.7 | 10 | (68) | ||
| LMB-75 | BCMA | PE24 | 1.1 | 100 | H929 | (69) |
| PE24 with 4 point mutations to reduce B cell binding | 3.1 | 35 | Unpublished | |||
| LMB-92 | ||||||
| LMB-103 (T20) | ||||||
| PE24 with 6 point mutations to reduce T cell binding | 6 | 18 | Unpublished | |||
| LMB-273 (T20) | PE24 with 5 point mutations to reduce T cell binding (excluding R494A) | 1.1 | 100 | Unpublished | ||
| HN3-PE38 | GPC3 | PE38 | 586.0 | 100 | Hep38B | |
| HN3-mPE24 | PE24 with 5 point mutations to reduce B cell binding | 592.0 | 99 | (70) | ||
| HN3-T20 | PE24 with 6 point mutations to reduce T cell binding | 766.0 | 77 | |||
| HN3-T19 | PE24 with 10 point mutations to reduce B and T cell binding | 1082.0 | 54 | |||